Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 3

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 3
---
 of us or to which we have referred you. Neither we nor the Selling Securityholder have authorized anyone to provide you with different information. Neither we nor the Selling Securityholder are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date of the applicable document. Since the date of this prospectus, our business, financial condition, results of operations and prospects may have changed.

For investors outside of
the United States: Neither we nor the Selling Securityholder have done anything that would permit this offering or possession or distribution
of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to
inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.

In this prospectus, “we,”
“us,” “our” and the “Company” refer to NewGenIvf Group Limited and its wholly owned subsidiary, NewGenIvf
Limited, a Cayman Islands company.

Our reporting currency is
the U.S. dollar. Unless otherwise expressly stated or the context otherwise requires, references in this prospectus to “dollars”
or “$” are to U.S. dollars.

This prospectus includes
statistical, market and industry data and forecasts which we obtained from publicly available information and independent industry publications
and reports that we believe to be reliable sources. These publicly available industry publications and reports generally state that they
obtain their information from sources that they believe to be reliable, but they do not guarantee the accuracy or completeness of the
information. Although we believe that these sources are reliable, we have not independently verified the information contained in such
publications.

Our consolidated financial
statements are prepared and presented in accordance with accounting principles generally accepted in the United States of America, or
U.S. GAAP.

The number of Class A
Ordinary Shares and Class B Ordinary Shares currently issued and outstanding was 2,952,702 as of October 31, 2025. No new shares are
being issued by the Company pursuant to this offering.

<div align='center'>ii

ABOUT THIS PROSPECTUS</div>

This prospectus describes
the general manner in which the Selling Securityholders identified in this prospectus may offer from time to time up to 50,000,000 Class
A Ordinary Shares through any means described in the section entitled